An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the ...

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores. Findings from a recently ...

Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...

Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles. This is an ASCO Meeting Abstract from the ...

In many countries where it is marketed as Somatuline ® Autogel ®, Somatuline ® is approved for treatment of acromegaly and for the symptoms associated with neuroendocrine tumors, which can include the ...

A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after ...

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline ® Depot 120mg injection for ...

Ipsen Biopharmaceuticals announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for Somatuline Depot (lanreotide acetate) 120mg injection for the treatment of ...

Treatment patterns among patients with metastatic GEP-NET treated at a tertiary referral center. Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic ...

Indications for Somatuline ® Depot include the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a ...

David Johnson, Global Director, Commercial Excellence, ADVANZ PHARMA said: “Until now, prescriber choice has been limited. The launch of a generic alternative means we are able to improve access and ...